AbbVie competitors and similar companiesClear all

Astellas Pharma's competitors and similar companies include Gilead Sciences, Immunomedics, Sanofi, Amgen, Bristol-Myers Squibb, Abbott, Merck Group, GSK, Novartis, Roche and Johnson & Johnson.
Astellas Pharma
Astellas Pharma
Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.
Gilead Sciences
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
Immunomedics
Immunomedics
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
Sanofi
Sanofi
Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
Amgen
Amgen
Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products.
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb is a company focused that provides biopharmaceutical products.
Abbott
Abbott
Abbott Laboratories is a healthcare company that develops, manufactures, and sells health care products.
Merck Group
Merck Group
Merck Group is a pharmaceutical, chemical, and life sciences company.
GSK
GSK
GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products.
Novartis
Novartis
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
Roche
Roche
Roche Holding is the holding company of F. Hoffmann-La Roche, a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics.
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson is a global holding company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field.
Founding Date
Founding Date
1923
Founding Date
1987
Founding Date
1982
Founding Date
2004
Founding Date
1980
Founding Date
1887
Founding Date
1894
Founding Date
1668
Founding Date
2000
Founding Date
1996
Founding Date
1896
Founding Date
1886
Type
Type
Public
Type
Public
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Tokyo, JP HQ
Macquarie Park, AU
Wien, AT
Vilvoorde, BE
São Paulo, BR
Markham, CA
Beijing, CN
see more
Locations
Foster City, US HQ
Buenos Aires, AR
Melbourne, AU
Wien, AT
Machelen, BE
São Paulo, BR
Edmonton, CA
see more
Locations
Morris Plains, US HQ
Locations
Paris, FR HQ
Hydra, DZ
Macquarie Park, AU
Wien, AT
Dhaka, BD
Brussel, BE
Geel, BE
see more
Locations
Thousand Oaks, US HQ
Hydra, DZ
Vicente López, AR
Sydney, AU
Wien, AT
Diegem, BE
Santo Amaro, BR
see more
Locations
New York, US HQ
Wien, AT
Braine L'alleud, BE
Bruxelles, BE
São Paulo, BR
Montréal, CA
Shanghai, CN
see more
Locations
Abbott Park, US HQ
Tiranë, AL
Buenos Aires, AR
Yerevan, AM
Doncaster, AU
East Brisbane, AU
Macquarie Park, AU
see more
Locations
Darmstadt, DE HQ
Hydra, DZ
Buenos Aires, AR
Bayswater, AU
Macquarie Park, AU
Wien, AT
Manama, BH
see more
Locations
Brentford, GB HQ
Boumerdes, DZ
San Fernando, AR
Abbotsford, AU
Boronia, AU
Ermington, AU
Wien, AT
see more
Locations
Basel, CH HQ
Tirana, AL
Bir Mourad Raïs, DZ
Duc, AR
Macquarie Park, AU
Wien, AT
Baku, AZ
see more
Locations
Basel, CH HQ
Hydra, DZ
Ricardo Rojas, AR
North Ryde, AU
Sydney, AU
Wien, AT
Dhaka, BD
see more
Locations
New Brunswick, US HQ
Buenos Aires, AR
San Isidro, AR
Yerevan, AM
Sydney, AU
Ultimo, AU
Wien, AT
see more
Employees
Employees
15,4553% decrease
Employees
14,4006% increase
Employees
1324% decrease
Employees
95,4424% decrease
Employees
24,200
Employees
32,2006% increase
Employees
113,0004% increase
Employees
59,3086% decrease
Employees
90,0964% decrease
Employees
104,3231% decrease
Employees
100,9201% decrease
Employees
141,7005% increase
Valuation ($)
Valuation ($)
27.6 b
Valuation ($)
105 b
Valuation ($)
N/A
Valuation ($)
121.7 b
Valuation ($)
142.9 b
Valuation ($)
154 b
Valuation ($)
191.7 b
Valuation ($)
89.8 b
Valuation ($)
71.3 b
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
439.8 b
Twitter followers
Twitter followers
50.4 k
Twitter followers
73.1 k
Twitter followers
579
Twitter followers
150.8 k
Twitter followers
124.4 k
Twitter followers
157.3 k
Twitter followers
121.7 k
Twitter followers
24.6 k
Twitter followers
242.2 k
Twitter followers
302.8 k
Twitter followers
247.4 k
Twitter followers
250.2 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
25
Number of tweets (last 30 days)
1
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
21
Number of tweets (last 30 days)
42
Number of tweets (last 30 days)
11
Number of tweets (last 30 days)
139
Number of tweets (last 30 days)
32
Number of tweets (last 30 days)
38
Number of tweets (last 30 days)
32
Number of tweets (last 30 days)
29
Number of tweets (last 30 days)
30
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
5.8
Average likes per tweet (last 30 days)
22
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
8
Average likes per tweet (last 30 days)
5.5
Average likes per tweet (last 30 days)
8.5
Average likes per tweet (last 30 days)
4.1
Average likes per tweet (last 30 days)
1.9
Average likes per tweet (last 30 days)
11.5
Average likes per tweet (last 30 days)
5.9
Average likes per tweet (last 30 days)
5.2
Average likes per tweet (last 30 days)
4.7
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
96%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
71.43%
Percentage of tweets with engagement (last 30 days)
92.86%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
27.34%
Percentage of tweets with engagement (last 30 days)
90.63%
Percentage of tweets with engagement (last 30 days)
73.68%
Percentage of tweets with engagement (last 30 days)
71.88%
Percentage of tweets with engagement (last 30 days)
62.07%
Percentage of tweets with engagement (last 30 days)
50%
Alexa Website Rank
Alexa Website Rank
330601
Alexa Website Rank
187202
Alexa Website Rank
N/A
Alexa Website Rank
155495
Alexa Website Rank
118547
Alexa Website Rank
106029
Alexa Website Rank
78401
Alexa Website Rank
70623
Alexa Website Rank
23804
Alexa Website Rank
129099
Alexa Website Rank
46160
Alexa Website Rank
17146
Employee Rating
Employee Rating
4.2
Employee Rating
3.8
Employee Rating
2.9
Employee Rating
N/A
Employee Rating
4.1
Employee Rating
3.9
Employee Rating
3.9
Employee Rating
4.1
Employee Rating
4
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
4.2

Financial

Revenue (est.)
Revenue (est.)
¥1.3t (FY, 2022)
Revenue (est.)
$27.3b (FY, 2021)
Revenue (est.)
$295k (FY, 2019)
Revenue (est.)
€37.8b (FY, 2021)
Revenue (est.)
$26b (FY, 2021)
Revenue (est.)
$46.4b (FY, 2021)
Revenue (est.)
$43.1b (FY, 2021)
Revenue (est.)
€19.7b (FY, 2021)
Revenue (est.)
£34.1b (FY, 2021)
Revenue (est.)
$52.9b (FY, 2021)
Revenue (est.)
CHF62.8b (FY, 2021)
Revenue (est.)
$93.8b (FY, 2021)
Cost of goods
Cost of goods
¥173.3b (FY, 2022)
Cost of goods
$6.6b (FY, 2021)
Cost of goods
N/A
Cost of goods
(€10.7b) (FY, 2021)
Cost of goods
$6.5b (FY, 2021)
Cost of goods
$9.9b (FY, 2021)
Cost of goods
$18.5b (FY, 2021)
Cost of goods
€7.4b (FY, 2021)
Cost of goods
£11.6b (FY, 2021)
Cost of goods
$9.7b (FY, 2021)
Cost of goods
(CHF15.5b) (FY, 2021)
Cost of goods
$29.9b (FY, 2021)
Gross profit
Gross profit
¥1.2t (FY, 2022)
Gross profit
$20.7b (FY, 2021)
Gross profit
$295k (FY, 2019)
Gross profit
€28.9b (FY, 2021)
Gross profit
$19.5b (FY, 2021)
Gross profit
$36.4b (FY, 2021)
Gross profit
$24.5b (FY, 2021)
Gross profit
€12.3b (FY, 2021)
Gross profit
£22.5b (FY, 2021)
Gross profit
$45.1b (FY, 2021)
Gross profit
CHF50.4b (FY, 2021)
Gross profit
$63.9b (FY, 2021)
Net income
Net income
¥124.1b (FY, 2022)
Net income
$6.2b (FY, 2021)
Net income
($357.3m) (FY, 2019)
Net income
€6.2b (FY, 2021)
Net income
$5.9b (FY, 2021)
Net income
$7b (FY, 2021)
Net income
$7.1b (FY, 2021)
Net income
€3.1b (FY, 2021)
Net income
£5.1b (FY, 2021)
Net income
$24b (FY, 2021)
Net income
CHF14.9b (FY, 2021)
Net income
$20.9b (FY, 2021)

Operating

Countries
Countries
N/A
Countries
35 (FY, 2021)
Countries
N/A
Countries
N/A
Countries
100 (FY, 2020)
Countries
N/A
Countries
N/A
Countries
66 (FY, 2021)
Countries
92 (FY, 2021)
Countries
N/A
Countries
N/A
Countries
N/A
Manufacturing Facilities
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
8 (FY, 2021)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
85 (FY, 2021)
Manufacturing Sites
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
90 (FY, 2021)
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
23 (FY, 2019)
Manufacturing Sites
N/A
Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
405 (Sep, 2022)
Patents (US)
N/A
Patents (US)
31 (FY, 2020)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
20 (FY, 2020)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
16 (FY, 2021)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products (Immunology)
Phase I Trials Products (Immunology)
1 (Oct, 2020)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
6 (FY, 2021)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
4 (Jan, 2022)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Neuroscience)
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
4 (FY, 2021)
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
5 (Jan, 2022)
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
1 (FY, 2020)
Phase I Trials Products (Oncology)
7 (FY, 2019)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
9 (FY, 2021)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
20 (FY, 2021)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
36 (Jan, 2022)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Other)
Phase I Trials Products (Other)
3 (Oct, 2020)
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
2 (Jan, 2022)
Phase I Trials Products (Other)
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
5 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
6 (FY, 2021)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products (Immunology)
Phase II Trials Products (Immunology)
1 (Oct, 2020)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
6 (FY, 2021)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
6 (Jan, 2022)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
1 (FY, 2020)
Phase II Trials Products (Oncology)
1 (FY, 2021)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
12 (FY, 2021)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
15 (FY, 2021)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
11 (Jan, 2022)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Other)
Phase II Trials Products (Other)
2 (Oct, 2020)
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
3 (Jan, 2022)
Phase II Trials Products (Other)
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
9 (FY, 2021)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
11 (FY, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
11 (FY, 2021)
Phase III Trials Products
54 (FY, 2021)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products (Immunology)
Phase III Trials Products (Immunology)
1 (Oct, 2020)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
3 (FY, 2021)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
7 (Jan, 2022)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
4 (Oct, 2020)
Phase III Trials Products (Oncology)
4 (FY, 2021)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
7 (FY, 2021)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
27 (FY, 2021)
Phase III Trials Products (Oncology)
27 (Jan, 2022)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Other)
Phase III Trials Products (Other)
1 (Oct, 2020)
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
1 (Jan, 2022)
Phase III Trials Products (Other)
N/A
Products
Products
N/A
Products
21 (FY, 2021)
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Products
1.5 k (FY, 2019)
Products
300 k (FY, 2021)
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Research and Development Centers
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
11 (FY, 2021)
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
29 (FY, 2019)
Research and Development Centers
N/A
Suppliers
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
68 k (FY, 2019)
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
37.5 k (FY, 2021)
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
US FDA Breakthrough Therapy Designations
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
6 (FY, 2017)
US FDA Breakthrough Therapy Designations
2 (FY, 2021)
US FDA Breakthrough Therapy Designations
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 30m
Total funding raised
$ 310m
Total funding raised
N/A
Total funding raised
$ 15.5m
Total funding raised
N/A
Total funding raised
$ 121m
Total funding raised
N/A
Total funding raised
$ 6.5m
Total funding raised
$ 7.8b
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

Gilead Sciences
HQ
Foster City, US
Employees
14,400↑ 6% increase

Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.

View company
Immunomedics
HQ
Morris Plains, US

Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.

View company
Sanofi
HQ
Paris, FR
Employees
95,442↓ 4% decrease

Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.

View company
Amgen
HQ
Thousand Oaks, US
Employees
24,200

Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products.

View company